R K Ramanathan
Overview
Explore the profile of R K Ramanathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patnaik A, Appleman L, Tolcher A, Papadopoulos K, Beeram M, Rasco D, et al.
Ann Oncol
. 2016 Sep;
27(10):1928-40.
PMID: 27672108
Background: To evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of copanlisib, a phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL). Patients And...
2.
Ramanathan R, Korn R, Chiorean E, Liu H, Von Hoff D
Ann Oncol
. 2016 Jun;
27(8):1647-8.
PMID: 27240995
No abstract available.
3.
Chiorean E, Von Hoff D, Reni M, Arena F, Infante J, Bathini V, et al.
Ann Oncol
. 2016 Jan;
27(4):654-60.
PMID: 26802160
Background: A phase I/II study and subsequent phase III study (MPACT) reported significant correlations between CA19-9 decreases and prolonged overall survival (OS) with nab-paclitaxel plus gemcitabine (nab-P + Gem) treatment...
4.
Ramanathan R, Goldstein D, Korn R, Arena F, Moore M, Siena S, et al.
Ann Oncol
. 2016 Jan;
27(4):648-53.
PMID: 26802153
Background: In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the...
5.
Patnaik A, Weiss G, Papadopoulos K, Hofmeister C, Tibes R, Tolcher A, et al.
Br J Cancer
. 2014 Jun;
111(2):272-80.
PMID: 24901237
Background: Ficlatuzumab, a humanised hepatocyte growth factor (HGF) IgG1κ inhibitory monoclonal antibody, was evaluated for recommended phase II dose (RP2D), safety, pharmacokinetics (PKs), antidrug antibody (ADA), pharmacodynamics (PDs) and antitumour...
6.
Hochster H, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, et al.
Ann Oncol
. 2014 Mar;
25(6):1172-8.
PMID: 24608198
Background: Oxaliplatin is an integral component of colorectal cancer treatment, but its use is limited by neurotoxicity. The Combined Oxaliplatin Neurotoxicity Prevention Trial (CONcePT) tested intermittent oxaliplatin (IO) administration and...
7.
Mahadevan D, Chiorean E, Harris W, Von Hoff D, Stejskal-Barnett A, Qi W, et al.
Eur J Cancer
. 2012 Aug;
48(18):3319-27.
PMID: 22921184
Background: SF1126 is a peptidic pro-drug inhibitor of pan-PI3K/mTORC. A first-in-human study evaluated safety, dose limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of SF1126,...
8.
El-Khoueiry A, Ramanathan R, Yang D, Zhang W, Shibata S, Wright J, et al.
Invest New Drugs
. 2011 Mar;
30(3):1175-83.
PMID: 21424698
Purpose: Patients with metastatic pancreatic cancer have limited therapeutic options. The role of the Ras-Raf-MAPK pathway and of vascular endothelial growth factor in pancreatic carcinogenesis provided the rational to evaluate...
9.
Ramanathan R, Rothenberg M, de Gramont A, Tournigand C, Goldberg R, Gupta S, et al.
Ann Oncol
. 2009 Nov;
21(4):754-758.
PMID: 19887466
Background: The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence, severity, and/or course of peripheral sensory neuropathy (PSN) after oxaliplatin (FOLFOX)...
10.
Zamboni W, Strychor S, Maruca L, Ramalingam S, Zamboni B, Wu H, et al.
Clin Pharmacol Ther
. 2009 Aug;
86(5):519-26.
PMID: 19675541
S-CKD602 is a pegylated liposomal formulation of CKD-602. This study is the first to evaluate the factors affecting the high interpatient variability in the pharmacokinetic disposition of S-CKD602. S-CKD602 was...